![Barbara Klencke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barbara Klencke
Technik-/Wissenschafts-/F&E-Leiter bei
ALX ONCOLOGY HOLDINGS INC.
Vermögen: 374 714 $ am 31.05.2026
Profil
Barbara J.
Klencke is currently an Independent Director at Xencor, Inc. since 2023, Immune-Onc Therapeutics, Inc. since 2022, and TScan Therapeutics, Inc. since 2023.
Dr. Klencke is also set to be Chief Medical Officer at ALX Oncology Holdings, Inc. starting in 2025.
Former roles include Medical Director at Chiron Corp.
from 2002 to 2003, Group Medical Director-Product Development at Genentech, Inc. from 2003 to 2011, Senior Vice President-Global Development at Onyx Pharmaceuticals, Inc. from 2011 to 2015, Chief Medical & Development Officer at Sierra Oncology, Inc. from 2015 to 2022, Independent Director at Lexent Bio, Inc. from 2017 to 2020, Independent Director at eFFECTOR Therapeutics, Inc. from 2021 to 2024, and Assistant Professor-Medicine in Oncology at the University of California from 1995 to 2002.
Education includes undergraduate studies at Indiana University and a doctorate from the University of California, Davis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.04.2026 | 120’000 ( 0.09% ) | 228 000 $ | 31.05.2026 | |
| 20.05.2026 | 70’000 ( 0.11% ) | 75 600 $ | 31.05.2026 | |
XENCOR, INC. 0.01% | 28.02.2026 | 5’986 ( 0.01% ) | 71 114 $ | 31.05.2026 |
Aktive Positionen von Barbara Klencke
| Unternehmen | Position | Beginn |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 06.04.2023 |
| XENCOR, INC. | Direktor/Vorstandsmitglied | 15.09.2023 |
| ALX ONCOLOGY HOLDINGS INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.09.2025 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Direktor/Vorstandsmitglied | 08.11.2022 |
Ehemalige bekannte Positionen von Barbara Klencke
| Unternehmen | Position | Ende |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 21.06.2024 |
| SIERRA ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2022 |
Lexent Bio, Inc.
 Lexent Bio, Inc. Financial ConglomeratesFinance Develops novel liquid biopsy technologies to manage cancer | Direktor/Vorstandsmitglied | 01.01.2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01.06.2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01.01.2011 |
Ausbildung von Barbara Klencke
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
83
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Lexent Bio, Inc.
Lexent Bio, Inc. Financial ConglomeratesFinance Develops novel liquid biopsy technologies to manage cancer | Finance |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
eFFECTOR Therapeutics, Inc.
 eFFECTOR Therapeutics, Inc. BiotechnologyHealth Technology Operates as a oncology company which develops therapies for cancer | Health Technology |
